Cohort Study: Long‐Term Risk and Healthcare Burden of Irritable Bowel Syndrome Following Infection Enteritis in 202,244 Patients
Alimentary Pharmacology & Therapeutics · 2026-06 · 63 (11) · 1537-1548
DOI: 10.1111/apt.70602 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 13.03.2026. Verfasst von Mohamed H Eldesouki und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, New York Medical College at Saint Michael's Medical Center, Newark, New Jersey, USA. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Enteritis, Dyspepsia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Background
Infection enteritis is associated with the development of irritable bowel syndrome (IBS) and functional dyspepsia.
Aim
This study aimed to examine the long‐term risk of IBS and functional dyspepsia, and associated health care utilisation following infection enteritis.
Methods
We conducted a retrospective cohort study using TriNetX U.S. Network. Adults with infection enteritis were identified and matched to controls, balancing demographics and comorbidities. Primary outcomes were the risk of incident IBS and functional dyspepsia diagnoses at 1, 5, and 10 years. Secondary outcomes were rates of IBS‐ and functional dyspepsia‐related medications, endoscopy, abdominal imaging, and hospitalizations. Pathogen‐specific and multivariate analyses were performed to assess variations in IBS risk.
Results
After matching, 202,244 patients were identified in each study cohort. At 1 year of follow‐up, the infection enteritis cohort had higher rates of IBS (RR = 2.35; 95% CI: 2.14–2.59), functional dyspepsia (RR = 2.02; 95% CI: 1.84–2.22), use of IBS‐related medications (RR = 1.29; 95% CI: 1.26–1.31), functional dyspepsia‐related medications (RR = 1.56; 95% CI: 1.55–1.59), abdominal imaging (RR = 2.42; 95% CI: 2.29–2.54), and Oesophagogastroduodenoscopy/colonoscopy (RR = 1.57; 95% CI: 1.50–1.65). These risks remained significantly higher in the IE cohort at 5 and 10 years. Salmonella/Shigella (RR = 6.48), and Giardia lamblia (RR = 5.05) had the highest risk of developing incident IBS.
Conclusion
Infection enteritis was associated with increased risk of IBS and functional dyspepsia, rates of related medication use, and greater healthcare utilisation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, New York Medical College at Saint Michael's Medical Center, Newark, New Jersey, USA.
- Division of Gastroenterology and Hepatology, West Virginia University, Morgantown, West Virginia, USA.
- Division of Gastroenterology and Hepatology, Medical University of South Carolina, Charleston, South Carolina, USA.
- Division of Gastroenterology and Hepatology, Enteric Neuroscience Program, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Mohamed H Eldesouki, Mohammad Kloub, Khaled Elfert, Ahmed Ibrahim
Zitieren
APA
Eldesouki, M. H., Kloub, M., Elfert, K., Ibrahim, A., Grover, M., & Gayam, S. (2026). Cohort Study: Long‐Term Risk and Healthcare Burden of Irritable Bowel Syndrome Following Infection Enteritis in 202,244 Patients. Alimentary Pharmacology & Therapeutics, 63(11), 1537-1548. https://doi.org/10.1111/apt.70602
Vancouver
Eldesouki MH, Kloub M, Elfert K, Ibrahim A, Grover M, Gayam S. Cohort Study: Long‐Term Risk and Healthcare Burden of Irritable Bowel Syndrome Following Infection Enteritis in 202,244 Patients. Alimentary Pharmacology & Therapeutics. 2026;63(11):1537-1548. doi:10.1111/apt.70602
BibTeX
@article{Eldesouki2026,
author = {Eldesouki, Mohamed H and Kloub, Mohammad and Elfert, Khaled and Ibrahim, Ahmed and Grover, Madhusudan and Gayam, Swapna},
title = {Cohort Study: Long‐Term Risk and Healthcare Burden of Irritable Bowel Syndrome Following Infection Enteritis in 202,244 Patients},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {63},
number = {11},
pages = {1537--1548},
doi = {10.1111/apt.70602}
}
EUVIMED